Built from the ground up by physicians for physicians, StatRad has been passionately dedicated to providing the very best in patient care while constantly improving our service to our partners through the latest advances in technology. Established in 1996, we partnered with local radiology groups to provide coverage after normal business hours. In 2001, we introduced an innovative teleradiology platform to accelerate transmissions, streamline workflows, increase productivity and improve communication among physicians. Today, we’re maintaining our pioneering spirit by introducing new innovations to the market on a regular basis and providing the technology, expertise and service to help our clients deliver excellent care.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical, Industry Outlook

MUSTANG BIO ANNOUNCES FIRST DATA FROM ONGOING MULTICENTER PHASE 1/2 CLINICAL TRIAL EVALUATING MB-106 CAR-T CELL THERAPY

Globenewswire | August 17, 2023

news image

Mustang Bio Inc. a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced the first data from the indolent lymphoma cohort of the Company’s ongoing multicenter Phase 1/2 clinical trial evaluating MB-106, a first-in-class CD20-targeted, autologous CAR-T cell therapy for the treatment of relapsed or refractory B-cell non-...

Read More

Cell and Gene Therapy

PUMA BIOTECHNOLOGY ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH TAKEDA FOR THE DEVELOPMENT AND COMMERCIALIZATION OF ALISERTIB

Puma Biotechnology | September 21, 2022

news image

Puma Biotechnology, Inc. a biopharmaceutical company, announced an agreement with Takeda to license the worldwide research and development and commercial rights to alisertib, a selective, small-molecule, orally administered inhibitor of aurora kinase A. Alisertib is an adenosine triphosphate–competitive and reversible inhibitor of aurora kinase A and results in disruption of mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Alisertib h...

Read More

INRAE, EVOLUGATE ENTER OPTION LICENSE AGREEMENT TO ADVANCE PROBIOTICS TO MANAGE HUMAN CHOLESTEROL

Evolugate | May 28, 2020

news image

INRAE, is pleased to announce that it has entered into an exclusive option license agreement with biotechnology company Evolugate of Gainesville, FL to optimize its probiotic to manage human hypercholesterolemia, a major risk factor for cardiovascular diseases.INRAE is the first worldwide research institute in agronomy. INRAE-Micalis has been investigating the human microbiome to identify microbes that can influence hypercholesterolemia. They have selected microbes that degrade or sequeste...

Read More

Cell and Gene Therapy, Diagnostics

NORTHX BIOLOGICS, A LEADING NORDIC DEVELOPMENT AND MANUFACTURING ORGANISATION ANNOUNCES ACQUISITION OF A BIOLOGICS MANUFACTURING UNIT FROM VALNEVA

Globenewswire | July 04, 2023

news image

NorthX Biologics (‘NorthX’), a leading Nordic development and manufacturing organisation with a focus on advanced biologics, CGT (cell and gene therapy) and vaccines, announced today the successful acquisition of the Stockholm-based Clinical Trial Manufacturing unit from Valneva Sweden, significantly expanding capabilities. The acquisition includes the transfer of a multi-purpose facility, situated in the Stockholm life science cluster, close to Karolinska University...

Read More
news image

Medical, Industry Outlook

MUSTANG BIO ANNOUNCES FIRST DATA FROM ONGOING MULTICENTER PHASE 1/2 CLINICAL TRIAL EVALUATING MB-106 CAR-T CELL THERAPY

Globenewswire | August 17, 2023

Mustang Bio Inc. a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced the first data from the indolent lymphoma cohort of the Company’s ongoing multicenter Phase 1/2 clinical trial evaluating MB-106, a first-in-class CD20-targeted, autologous CAR-T cell therapy for the treatment of relapsed or refractory B-cell non-...

Read More
news image

Cell and Gene Therapy

PUMA BIOTECHNOLOGY ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH TAKEDA FOR THE DEVELOPMENT AND COMMERCIALIZATION OF ALISERTIB

Puma Biotechnology | September 21, 2022

Puma Biotechnology, Inc. a biopharmaceutical company, announced an agreement with Takeda to license the worldwide research and development and commercial rights to alisertib, a selective, small-molecule, orally administered inhibitor of aurora kinase A. Alisertib is an adenosine triphosphate–competitive and reversible inhibitor of aurora kinase A and results in disruption of mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Alisertib h...

Read More
news image

INRAE, EVOLUGATE ENTER OPTION LICENSE AGREEMENT TO ADVANCE PROBIOTICS TO MANAGE HUMAN CHOLESTEROL

Evolugate | May 28, 2020

INRAE, is pleased to announce that it has entered into an exclusive option license agreement with biotechnology company Evolugate of Gainesville, FL to optimize its probiotic to manage human hypercholesterolemia, a major risk factor for cardiovascular diseases.INRAE is the first worldwide research institute in agronomy. INRAE-Micalis has been investigating the human microbiome to identify microbes that can influence hypercholesterolemia. They have selected microbes that degrade or sequeste...

Read More
news image

Cell and Gene Therapy, Diagnostics

NORTHX BIOLOGICS, A LEADING NORDIC DEVELOPMENT AND MANUFACTURING ORGANISATION ANNOUNCES ACQUISITION OF A BIOLOGICS MANUFACTURING UNIT FROM VALNEVA

Globenewswire | July 04, 2023

NorthX Biologics (‘NorthX’), a leading Nordic development and manufacturing organisation with a focus on advanced biologics, CGT (cell and gene therapy) and vaccines, announced today the successful acquisition of the Stockholm-based Clinical Trial Manufacturing unit from Valneva Sweden, significantly expanding capabilities. The acquisition includes the transfer of a multi-purpose facility, situated in the Stockholm life science cluster, close to Karolinska University...

Read More

Resources

resource image

Cell and Gene Therapy, Industrial Impact

Asia Pacific Leads The Way In Cell & Gene Therapy Trials

Whitepaper

resource image

Cell and Gene Therapy, Industrial Impact

GMP Grade PMSF and Protease Inhibitors

Whitepaper

resource image

Cell and Gene Therapy, Industrial Impact

Asia Pacific Leads The Way In Cell & Gene Therapy Trials

Whitepaper

resource image

Cell and Gene Therapy, Industrial Impact

GMP Grade PMSF and Protease Inhibitors

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us